Semaglutide timeline: what the published trials and research reports show
Semaglutide has the largest published trial base of any GLP-1 compound on this site, which makes it a useful anchor for what a titration timeline actually looks like in controlled research. Two separate things get asked about in the same breath, tolerability week to week, and the weight change the trials reported, so this splits them out clearly.
What the published trial reported
| Trial | STEP 1 (NEJM, 2021) |
| Population | Adults with obesity or overweight, no diabetes |
| Dose | 2.4 mg once weekly, titrated over 16 to 20 weeks |
| Duration | 68 weeks |
| Result | Mean body weight change of -14.9%, versus -2.4% on placebo |
| 5%+ responders | 86.4% of participants, versus 31.5% on placebo |
This is trial-level data under medical supervision and a structured lifestyle program, on pharmaceutical-grade product. It describes what the trial measured, not a personal outcome to expect from research use.
Weeks 1 to 4: the lowest doses
The trial titration opens at 0.25 mg weekly, a dose chosen for tolerability rather than effect. GI symptoms, mainly nausea, are the most commonly reported issue in this window, and are generally described as mild and transient. Appetite change is commonly reported earlier than the GI symptoms resolve.
Weeks 5 to 16: the climb to maintenance
The dose steps up roughly every four weeks toward the 2.4 mg maintenance level. Each step is commonly associated with a short-lived return of GI symptoms in both trial data and wider reporting, which is the basis for titrating slowly rather than starting near the maintenance dose.
Weeks 16 to 68: sustained change
Trial data shows weight change continuing to build well past the point where the dose stabilizes, with the STEP 1 trial recording its nadir well into the second year in extension follow-up. GI tolerability, meanwhile, is reported to improve substantially once the dose has been steady for a few weeks.
Common questions
Does the trial figure apply to research-grade product at home? The 14.9% figure reflects supervised dosing of an approved pharmaceutical product alongside structured lifestyle support, not an unsupervised research context. Treat it as a research reference point on scale, not a personal projection.
Why does nausea come back with each dose increase? GLP-1 receptor activity slows gastric emptying, and each increase in receptor activation is commonly reported to bring a short readjustment before tolerance rebuilds.
How does this compare to tirzepatide? Tirzepatide's SURMOUNT-1 trial reported roughly 15 to 21 percent weight change depending on dose, in a similarly titrated, supervised trial. Dual versus single incretin action is the mechanistic difference behind the gap.
For the full mechanism, titration schedule and citations, see the semaglutide reference page.